Status:
NOT_YET_RECRUITING
Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment
Lead Sponsor:
First Affiliated Hospital, Sun Yat-Sen University
Conditions:
Renal Cell Carcinoma
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Whether patients with stage III clear cell renal cell carcinoma (ccRCC) should receive adjuvant targeted therapy or not is still on debate. The investigators invented a multimodal recurrence scoring s...
Eligibility Criteria
Inclusion
- The informed consent has been obtained from the patient.
- With confirmed diagnosis of stage III clear cell renal cell carcinoma
- With moderate/good Eastern Cooperative Oncology Group (ECOG) health rating (PS): 0-1 score.
- The patient receive no anti-cancer treatment before primary surgery.
- The patient receive radical operation for renal cancer with negative margin.
Exclusion
- Patients who have previously received neoadjuvant therapy
- With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.
- With bad compliance or contraindication to enrollment.
- Pregnant woman or lactating woman.
- With contraindication to receive adjuvant targeted therapy.
Key Trial Info
Start Date :
October 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2033
Estimated Enrollment :
488 Patients enrolled
Trial Details
Trial ID
NCT06032728
Start Date
October 1 2023
End Date
October 1 2033
Last Update
September 13 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.